Elisabeth A. Minthorn

Discovery of 7-Methyl-5-(1-{[3-(trifluoromethyl)phenyl]acetyl}-2,3-dihydro-1<i>H</i>-indol-5-yl)-7<i>H</i>-pyrrolo[2,3-<i>d</i>]pyrimidin-4-amine (GSK2606414), a Potent and Selective First-in-Class Inhibitor of Protein Kinase R (PKR)-like Endoplasmic Reticulum Kinase (PERK)

Jeffrey M. Axten, Jesús R. Medina, Yanhong Feng et al. · Journal of Medicinal Chemistry · 2012 · 601 citations · Full text

Chemoprevention Strategy, Chemical Biology, Pharmaceutical Chemistry +24

GSK1120212 (JTP-74057) Is an Inhibitor of MEK Activity and Activation with Favorable Pharmacokinetic Properties for Sustained <i>In Vivo</i> Pathway Inhibition

Aidan G. Gilmartin, Maureen R. Bleam, Arthur Groy et al. · Clinical Cancer Research · 2011 · 590 citations · Full text

Characterization of a Novel PERK Kinase Inhibitor with Antitumor and Antiangiogenic Activity

Charity Atkins, Qi Liu, Elisabeth A. Minthorn et al. · Cancer Research · 2013 · 426 citations

Tumor Biology, Signaling Pathway, Upr Signaling +21

Characterization of an Akt Kinase Inhibitor with Potent Pharmacodynamic and Antitumor Activity

Nelson Rhodes, Dirk A. Heerding, Derek R. Duckett et al. · Cancer Research · 2008 · 296 citations · Full text

Tumor Xenografts, Antitumor Activity, Chemoprevention Strategy +21

Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia

Melissa B. Pappalardi, Kathryn Keenan, Mark Cockerill et al. · Nature Cancer · 2021 · 251 citations · Full text

Hematological Malignancy, Medicine, Acute Myeloid Leukemia +9